Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques

Journal of Mass Spectrometry

Volumn 41, Issue 4, 2006, Pages 487-498

  Ewald, Andreas H ^a   Fritschi, Giselher ^b   Bork, Wolf Rainer ^c   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Hessisches Landeskriminalamt   (Germany)

^c Landeskriminalamt Berlin   (Germany)

Author keywords

DOB; GC MS; MDOB; Metabolism; Urinalysis

Indexed keywords

ACETONE; ALCOHOLS; AMINES; CHEMICAL REACTIONS; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; TOXICITY;

DOB; GC/MS; METHAMPHETAMINE (MDOB); SYSTEMATIC TOXICOLOGICAL ANALYSIS (STA); URINALYSIS;

DRUG PRODUCTS;

2,5 DIMETHOXY 4 BROMOMETHAMPHETAMINE; ALCOHOL; BROLAMFETAMINE; DESIGNER DRUG; DRUG METABOLITE; KETONE; N DEMETHYLASE; O DEMETHYLASE; UNCLASSIFIED DRUG;

ACETYLATION; AEROBIC METABOLISM; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEAMINATION; DRUG CONJUGATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; MICROWAVE RADIATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RAT; TOXICOLOGY; URINALYSIS;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ANIMALS; DESIGNER DRUGS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE DETECTION; URINALYSIS;

ANIMALIA;

EID: 33646376667     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.1007     Document Type: Article

References (26)

1. Barfknecht CF, Nichols DE. Potential psychotomimetics. Bromomethoxyamphetamines. J. Med. Chem. 1971; 14: 370.
2. Delliou D. 4-bromo-2,5-dimethoxyamphetamine: psychoactivity, toxic effects and analytical methods. Forensic Sci. Int. 1983; 21: 259.
3. Monte AP, Marona-Lewicka D, Parker MA, Wainscott DB, Nelson DL, Nichols DE. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 1996; 39: 2953.
4. Shulgin A, Pihkal A, Chemical Love Story. 1st Transform Press: Berkley, 1991.
5. Kalix P, Glennon RA. Further evidence for an amphetamine-like mechanism of action of the alkaloid cathinone. Biochem. Pharmacol. 1986; 35: 3015.
6. Bowen JS, Davis GB, Kearney TE, Bardin J. Diffuse vascular spasm associated with 4-bromo-2,5-dimethoxyamphetamine ingestion. JAMA 1983; 249: 1477.
7. Furnari C, Ottaviano V, Rosati F. Determination of 4-bromo-2,5-dimethoxyamphetamine (DOB) found in illicit tablets seized in Italy. Ann. Ist. Super. Sanita 2001; 37: 297.
8. Buhrich N, Morris G, Cook G. Bromo-DMA: the Australasian hallucinogen? Aust. N. Z. J. Psychiatry 1983; 17: 275.
9. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci. Int. 2005; 153: 85.
10. Winek CL, Collom WD, Bricker JD. A death due to 4-bromo-2,5-dimethoxyamphetamine. Clin. Toxicol. 1981; 18: 267.
11. Glennon RA, Yousif M, Naiman N, Kalix P. Methcathinone: a new and potent amphetamine-like agent. Pharmacol. Biochem. Behav. 1987; 26: 547.
12. Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, of amphetamine, methamphetamine and their N-alkyl derivatives [review]. Ther. Drug Monit. 2002; 24: 277.
13. Staack RF, Maurer HH. Metabolism of designer drugs of abuse [review]. Curr. Drug Metab. 2005; 6: 259.
14. Battu C, Marquet P, Fauconnet AL, Lacassie E, Lachatre G. Screening procedure for 21 amphetamine-related compounds in urine using solid-phase microextraction and gas chromatography-mass spectrometry. J. Chromatogr. Sci. 1998; 36: 1.
15. Maurer HH. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and / or doping control [review]. Clin. Chem. Lab. Med. 2004; 42: 1310.
16. Ewald AH, Peters FT, Weise M, Maurer HH. Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gaschromatography-massspectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 824: 123.
17. Theobald DS, Fehn S, Maurer HH. New designer drug 2,5-dimethoxy-4-propylthiophenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography / mass spectrometry. J. Mass Spectrom. 2005; 40: 105.
18. Theobald DS, Staack RF, Puetz M, Maurer HH. New designer drug 2,5-dimethoxy-4-ethylthio-beta-phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography / mass spectrometry. J. Mass Spectrom. 2005; 40: 1157.
19. McKay AF, Ott WL, Taylor GW, Buchanan MN, Crooker JF. Diazohydrocarbons. Can. J. Res. 1950; 28: 683.
20. Pfleger K, Maurer HH, Weber A. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites. 4th Agilent Technologies: Palo Alto, 2006; in preparation.
21. McLafferty FW, Turecek F. Interpretation of Mass Spectra. 4th University Science Books: Mill Valley, 1993.
22. Smith RM, Busch KL. Understanding Mass Spectra - A Basic Approach. Wiley: New York, 1999.
23. Kovats E. Gaschromatographische charakterisierung organischer verbindungen. Teil 1. Retentionsindices aliphatischer halogenide, alkohole, aldehyde und ketone. Helv. Chim. Acta 1958; 41: 1915.
24. de-Zeeuw RA, Franke JP, Maurer HH, Pfleger K. Gas Chromatographic Retention Indices of Toxicologically Relevant Substances and their Metabolites (Report of the DFG Commission for Clinical Toxicological Analysis, Special Issue of the TIAFT Bulletin). 3rd VCH Publishers: Weinheim, New York, Basle, 1992.
25. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and the toxicological analysis of the new piperazine-like designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002; 773: 35.
26. Bickeboeller-Friedrich J, Maurer HH. Screening for detection of new antidepressants, neuroleptics, hypnotics, and their metabolites in urine by GC-MS developed using rat liver microsomes. Ther. Drug Monit. 2001; 23: 61.